chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 70.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Expired product administered, Interchange of vaccine products
Clinical narrative: Interchange of vaccine product; Patient given expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine product) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) injection for COVID-19 vaccination.    No Medical History information was reported.   On 05-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 05-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine product). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine product) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The vial was expired on 01June2021 and the doses were given on 05June2021. No concomitant medication information provided. No treatment information provided.   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: Pfizer report was obtained as the follow up, co-suspect added, event added
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling cold, Hot flush, Pyrexia, Rash, Rash pruritic
Clinical narrative: Itchy rash; rash on the increase of arm, chest, belly, belly button, over her shoulders, and down the underarm areas.; Fever; Hot and cold flashes; Hot and cold flushes; This spontaneous case was reported by a consumer and describes the occurrence of HOT FLUSH (Hot and cold flashes), FEELING COLD (Hot and cold flushes), RASH PRURITIC (Itchy rash), RASH (rash on the increase of arm, chest, belly, belly button, over her shoulders, and down the underarm areas.) and PYREXIA (Fever) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and High cholesterol. Concomitant products included CALCIUM and VITAMIN B12 [VITAMIN B12 NOS] for an unknown indication.   On 05-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Jun-2021, the patient experienced HOT FLUSH (Hot and cold flashes), FEELING COLD (Hot and cold flushes) and PYREXIA (Fever). On 06-Jun-2021, the patient experienced RASH PRURITIC (Itchy rash) and RASH (rash on the increase of arm, chest, belly, belly button, over her shoulders, and down the underarm areas.). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Rash and Itchy rash, at an unspecified dose and frequency and PARACETAMOL (TYLENOL) for Fever, at an unspecified dose and frequency. At the time of the report, HOT FLUSH (Hot and cold flashes), FEELING COLD (Hot and cold flushes), RASH PRURITIC (Itchy rash), RASH (rash on the increase of arm, chest, belly, belly button, over her shoulders, and down the underarm areas.) and PYREXIA (Fever) outcome was unknown.
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Somnolence
Clinical narrative: Sleepy; Taste was off; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (Sleepy) and AGEUSIA (Taste was off) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE (Sleepy) and AGEUSIA (Taste was off). At the time of the report, SOMNOLENCE (Sleepy) and AGEUSIA (Taste was off) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No concomitant medications were provided by the reporter.  Treatment information was not provided.   This case was linked to MOD-2021-211538 (Patient Link).
Age: 13.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, Interchange of vaccine products, Product administered to patient of inappropriate age
Clinical narrative: Interchange of vaccine products; Patient given expired vaccine; Patient 13 years old (under 18 years old); This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine), PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient 13 years old (under 18 years old)) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 13-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 05-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient received dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On 05-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient 13 years old (under 18 years old)). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). On 05-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Patient given expired vaccine) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient 13 years old (under 18 years old)) had resolved. At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication were provided by the reporter.  No treatment medications were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: Pfizer report received contains information regarding new events, interchange of vaccine products.
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Myalgia, Pain in jaw, Somnolence
Clinical narrative: sleepy; didn't have much energy; experienced jaw pain on his left side; soreness in arm; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (sleepy), ASTHENIA (didn't have much energy), PAIN IN JAW (experienced jaw pain on his left side) and MYALGIA (soreness in arm) in a 91-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     The patient's past medical history included Stroke and Defibrillator/pacemaker insertion (had a stroke and has a defibrillator) since an unknown date.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE (sleepy), ASTHENIA (didn't have much energy), PAIN IN JAW (experienced jaw pain on his left side) and MYALGIA (soreness in arm). At the time of the report, SOMNOLENCE (sleepy), ASTHENIA (didn't have much energy), PAIN IN JAW (experienced jaw pain on his left side) and MYALGIA (soreness in arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were provided. No treatment information was provided.    This case was linked to MOD-2021-211520 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: consumer with 2nd dose of Moderna COVID-19 vaccine at day 21; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (consumer with 2nd dose of Moderna COVID-19 vaccine at day 21) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (consumer with 2nd dose of Moderna COVID-19 vaccine at day 21). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (consumer with 2nd dose of Moderna COVID-19 vaccine at day 21) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication reported by the reporter. No treatment medications were reported by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Non-significant follow up received - contact information updated
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Dizziness, Dyspnoea, Palpitations, Productive cough
Clinical narrative: Producing mucus ball; Vomited; Heart racing; Really dizzy; Difficulty breathing like her lungs were deflating; Coughing; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Heart racing), DIZZINESS (Really dizzy), DYSPNOEA (Difficulty breathing like her lungs were deflating), COUGH (Coughing) and PRODUCTIVE COUGH (Producing mucus ball) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036CZ1A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included METOPROLOL, HYDROCHLOROTHIAZIDE, CELECOXIB (CELEBREX), GABAPENTIN, LAMOTRIGINE (LAMICTAL), LEVOCETIRIZINE, OXYBUTYNIN, PANTOPRAZOLE, PRAZOSIN, DESVENLAFAXINE and ACETYLSALICYLIC ACID (ASPIRIN COX [ACETYLSALICYLIC ACID]) for an unknown indication.    On 04-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Jun-2021, the patient experienced PALPITATIONS (Heart racing), DIZZINESS (Really dizzy), DYSPNOEA (Difficulty breathing like her lungs were deflating), COUGH (Coughing) and VOMITING (Vomited). On 07-Jun-2021, the patient experienced PRODUCTIVE COUGH (Producing mucus ball). On 04-Jun-2021, VOMITING (Vomited) had resolved. At the time of the report, PALPITATIONS (Heart racing), DIZZINESS (Really dizzy), DYSPNOEA (Difficulty breathing like her lungs were deflating), COUGH (Coughing) and PRODUCTIVE COUGH (Producing mucus ball) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Treatment information was provided.    Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: Follow - Up document contains No New Information On 05-Aug-2021: Follow up document contains No New Information
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Producing mucus ball; Vomited; Heart racing; Really dizzy; Difficulty breathing like her lungs were deflating; Coughing; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Heart racing), DIZZINESS (Really dizzy), DYSPNOEA (Difficulty breathing like her lungs were deflating), COUGH (Coughing) and PRODUCTIVE COUGH (Producing mucus ball) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036CZ1A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included METOPROLOL, HYDROCHLOROTHIAZIDE, CELECOXIB (CELEBREX), GABAPENTIN, LAMOTRIGINE (LAMICTAL), LEVOCETIRIZINE, OXYBUTYNIN, PANTOPRAZOLE, PRAZOSIN, DESVENLAFAXINE and ACETYLSALICYLIC ACID (ASPIRIN COX [ACETYLSALICYLIC ACID]) for an unknown indication.    On 04-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Jun-2021, the patient experienced PALPITATIONS (Heart racing), DIZZINESS (Really dizzy), DYSPNOEA (Difficulty breathing like her lungs were deflating), COUGH (Coughing) and VOMITING (Vomited). On 07-Jun-2021, the patient experienced PRODUCTIVE COUGH (Producing mucus ball). On 04-Jun-2021, VOMITING (Vomited) had resolved. At the time of the report, PALPITATIONS (Heart racing), DIZZINESS (Really dizzy), DYSPNOEA (Difficulty breathing like her lungs were deflating), COUGH (Coughing) and PRODUCTIVE COUGH (Producing mucus ball) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Treatment information was provided.    Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: Follow - Up document contains No New Information On 05-Aug-2021: Follow up document contains No New Information
Sex: U
Vaccine: COVID19
Symptoms: Dyspnoea
Clinical narrative: trouble breathing 24 hours after 2nd dose; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 23-May-2021 and was forwarded to Moderna on 07-Jun-2021.    Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (trouble breathing 24 hours after 2nd dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No medical history was reported.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage form. On an unknown date, the patient experienced DYSPNOEA (trouble breathing 24 hours after 2nd dose). At the time of the report, DYSPNOEA (trouble breathing 24 hours after 2nd dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported , No treatment medication was reported .   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Mass
Clinical narrative: bumps on arms,bumps on chest,bumps on upper bra area; This spontaneous case was reported by a consumer and describes the occurrence of MASS (bumps on arms,bumps on chest,bumps on upper bra area) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MASS (bumps on arms,bumps on chest,bumps on upper bra area). At the time of the report, MASS (bumps on arms,bumps on chest,bumps on upper bra area) outcome was unknown.            No concomitant medication was reported. No treatment medication was reported.  Action taken in response to Moderna Covid 19 vaccine (mRNA 1273 vaccine ) is not applicable
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pain in extremity, Pyrexia, Vaccination site rash
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of pain in extremity (arm pain), vaccination site rash (rash on her arm), pyrexia (fever) and chills in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. On May 26, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On May 26, 2021, patient experienced pain in extremity (arm pain), vaccination site rash (rash on her arm), pyrexia (fever) and chills. At the time of the report, pain in extremity (arm pain), vaccination site rash (rash on her arm), pyrexia (fever) and chills outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. No concomitant medication or treatment information provided.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Mucous stools
Clinical narrative: mucus in stool; This spontaneous case was reported by a consumer and describes the occurrence of MUCOUS STOOLS (mucus in stool) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017C21A and 021C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Jun-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MUCOUS STOOLS (mucus in stool). At the time of the report, MUCOUS STOOLS (mucus in stool) outcome was unknown.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient reported that she  did not self treat and notified healthcare provider.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, SARS-CoV-2 test, Thyroid function test
Clinical narrative: Headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     The patient's past medical history included MTHFR gene mutation in 2000 and Heart murmur in 2000. Concurrent medical conditions included Allergic reaction to antibiotics, Dust allergy, Ragweed allergy, Food allergy, Migraine (Migraine severity has been worse), Hypothyroidism, Hashimoto's thyroiditis (The patient had been on Armour Thyroid medication 22mg for years, Abnormal TSH level/ thyroid medicine discontinued) since 2000 and Osteoporosis (But before vaccine) since 2006.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 06-Mar-2021, the patient experienced HEADACHE (Headache). The patient was treated with DIAZEPAM (rectal) ongoing since an unknown date for Spasms, at a dose of 10 mg once a day; ACETYLSALICYLIC ACID (ASPIRIN 81) ongoing since an unknown date for Clotting disorder, at a dose of 81 mg once a day; UBROGEPANT (UBRELVY) (oral) ongoing since an unknown date for Migraine, at a dose of 100 milligram; THYROID (ARMOUR THYROID) (oral) for Hypothyroidism, at a dose of 22 mg once a day and DIHYDROERGOTAMINE MESILATE (MIGRANAL) (nasal) ongoing since an unknown date for Migraine, at a dose of 1 dosage form. At the time of the report, HEADACHE (Headache) had resolved with sequelae.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2020, SARS-CoV-2 test: negative (Negative) Rapid(PCR was negative) Date:11/???/2020. In 2020, Thyroid function test: extremely low (Low) Extremely low, , despite being on Armour, which she had been taking for years.. On 25-Feb-2021, Thyroid function test: low (Low) Recovered with residual effect.. On 30-Mar-2021, Thyroid function test: abnormal (abnormal) Result was abnormal when retested.. On 30-Apr-2021, Thyroid function test: low normal (Inconclusive) Result was Low normal. On 01-Jun-2021, Thyroid function test: normal (normal) Patient latest test indicated patient's thyroid stimulating hormone level(TSH) was starting to come back to normal..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant information was not reported.   Most recent FOLLOW-UP information incorporated above includes: On 07-Jul-2021: Follow up received and contains significant information: Patient demographics, medical history, lab data, concomitant medications and events was added and event date was updated.
Sex: U
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: I have my first dosis of Moderna last april 18th; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (I have my first dosis of Moderna last april 18th) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (I have my first dosis of Moderna last april 18th). At the time of the report, PRODUCT DOSE OMISSION ISSUE (I have my first dosis of Moderna last april 18th) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications provided by the reporter. No treatment medications were reported by the reporter. .
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Vaccination site mass, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Vaccination site lump; vaccination site warmth; it got bigger and looks worse; Inappropriate schedule of vaccine administered; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (Vaccination site lump), VACCINATION SITE WARMTH (vaccination site warmth), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) and VACCINATION SITE SWELLING (it got bigger and looks worse) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 049C21A and 037A21B) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included VITAMINS NOS and COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]) for an unknown indication.   On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). On 05-Jun-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE MASS (Vaccination site lump), VACCINATION SITE WARMTH (vaccination site warmth) and VACCINATION SITE SWELLING (it got bigger and looks worse). The patient was treated with IBUPROFEN for Vaccination site mass, at an unspecified dose and frequency; NAPROXEN for Vaccination site mass, at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Vaccination site mass, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE MASS (Vaccination site lump), VACCINATION SITE WARMTH (vaccination site warmth) and VACCINATION SITE SWELLING (it got bigger and looks worse) outcome was unknown and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved.            Concomitant medications also include Two medications for anxiety,Medication for reflux, Medication that is not daily for diaphragm spasm, but patient hadn't taken it in a month.  Action taken with mRNA 1273 in response to event was not applicable.
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia
Clinical narrative: prolonged joint pain; prolonged muscle pain; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (prolonged joint pain) and MYALGIA (prolonged muscle pain) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (prolonged joint pain) and MYALGIA (prolonged muscle pain). At the time of the report, ARTHRALGIA (prolonged joint pain) and MYALGIA (prolonged muscle pain) outcome was unknown.            No concomitant medications were reported. No treatment information was reported.
Sex: U
Vaccine: COVID19
Symptoms: Heart rate increased
Clinical narrative: fast heart rate; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (fast heart rate) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEART RATE INCREASED (fast heart rate). At the time of the report, HEART RATE INCREASED (fast heart rate) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported  No treatment drugs were reported
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: severe reaction to the vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (severe reaction to the vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (severe reaction to the vaccine). At the time of the report, VACCINATION COMPLICATION (severe reaction to the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant and treatment information was reported by the reporter.
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Hyperaesthesia teeth, Myalgia, Pain in jaw, Somnolence
Clinical narrative: soreness in arm; didn't have much energy; sleepy; experienced jaw pain on his left side/more jaw pain; teeth were sensitive to cold; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (soreness in arm), ASTHENIA (didn't have much energy), SOMNOLENCE (sleepy), PAIN IN JAW (experienced jaw pain on his left side/more jaw pain) and HYPERAESTHESIA TEETH (teeth were sensitive to cold) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (soreness in arm), ASTHENIA (didn't have much energy), SOMNOLENCE (sleepy), PAIN IN JAW (experienced jaw pain on his left side/more jaw pain) and HYPERAESTHESIA TEETH (teeth were sensitive to cold). At the time of the report, MYALGIA (soreness in arm), ASTHENIA (didn't have much energy), SOMNOLENCE (sleepy), PAIN IN JAW (experienced jaw pain on his left side/more jaw pain) and HYPERAESTHESIA TEETH (teeth were sensitive to cold) outcome was unknown.            No concomitant medication details was reported. No treatment medication details was reported.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Beyond 42 days post first vaccine, Not received the Second Dose; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Beyond 42 days post first vaccine, Not received the Second Dose) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jun-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Beyond 42 days post first vaccine, Not received the Second Dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Beyond 42 days post first vaccine, Not received the Second Dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported by the reporter. No treatment medicationa were reported by the reporter.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Product administered to patient of inappropriate age
Clinical narrative: 16 years old patient got 2 doses of the Moderna COVID-19 vaccine; second dose was 40 days after the first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 years old patient got 2 doses of the Moderna COVID-19 vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was 40 days after the first dose) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004C21A and 007C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-May-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 years old patient got 2 doses of the Moderna COVID-19 vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was 40 days after the first dose). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 years old patient got 2 doses of the Moderna COVID-19 vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was 40 days after the first dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported by the reporter. No treatment medications were reported by the reporter.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Asthenia, Chills, Decreased appetite
Clinical narrative: no appetite; no taste; no smell; feeling weak; chills; headache; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE (no appetite), AGEUSIA (no taste), ANOSMIA (no smell), ASTHENIA (feeling weak) and CHILLS (chills) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included MULTIVITAMIN [VITAMINS NOS] and VITAMIN C [ASCORBIC ACID] for an unknown indication.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced DECREASED APPETITE (no appetite), AGEUSIA (no taste), ANOSMIA (no smell), ASTHENIA (feeling weak), CHILLS (chills) and HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) for Headache, at an unspecified dose and frequency. On 31-Mar-2021, DECREASED APPETITE (no appetite), ASTHENIA (feeling weak), CHILLS (chills) and HEADACHE (headache) had resolved. At the time of the report, AGEUSIA (no taste) and ANOSMIA (no smell) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) COVID-19 test negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   As treatment patient also took steroids and sinus cocktails for the symptoms.   This case was linked to MOD-2021-211544 (Patient Link).
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, SARS-CoV-2 test
Clinical narrative: no appetite; no taste; no smell; feeling weak; chills; headache; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE (no appetite), AGEUSIA (no taste), ANOSMIA (no smell), ASTHENIA (feeling weak) and CHILLS (chills) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included MULTIVITAMIN [VITAMINS NOS] and VITAMIN C [ASCORBIC ACID] for an unknown indication.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced DECREASED APPETITE (no appetite), AGEUSIA (no taste), ANOSMIA (no smell), ASTHENIA (feeling weak), CHILLS (chills) and HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) for Headache, at an unspecified dose and frequency. On 31-Mar-2021, DECREASED APPETITE (no appetite), ASTHENIA (feeling weak), CHILLS (chills) and HEADACHE (headache) had resolved. At the time of the report, AGEUSIA (no taste) and ANOSMIA (no smell) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) COVID-19 test negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   As treatment patient also took steroids and sinus cocktails for the symptoms.   This case was linked to MOD-2021-211544 (Patient Link).
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Vaccination site rash
Clinical narrative: Immediately following I had a sore arm at the injection site.; Immediately following I had a very slight rash at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Immediately following I had a sore arm at the injection site.) and VACCINATION SITE RASH (Immediately following I had a very slight rash at the injection site) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced MYALGIA (Immediately following I had a sore arm at the injection site.) and VACCINATION SITE RASH (Immediately following I had a very slight rash at the injection site). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency; CLOBETASOL (topical) at an unspecified dose and frequency and HYDROCORTISONE (topical) at an unspecified dose and frequency. On 17-Mar-2021, MYALGIA (Immediately following I had a sore arm at the injection site.) and VACCINATION SITE RASH (Immediately following I had a very slight rash at the injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications reported.    This case was linked to MOD-2021-211541 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Colitis
Clinical narrative: colitis; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of COLITIS (colitis) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COLITIS (colitis). At the time of the report, COLITIS (colitis) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications provided. No treatment information provided.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Patient is 16 years of age; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient is 16 years of age) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient is 16 years of age). On 20-Apr-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient is 16 years of age) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that a 16 years old patient got 2 doses of vaccine. The patient experienced no issues with the 2 doses and the patient was not on any medications on daily basis.   This case was linked to MOD-2021-211522 (Patient Link).
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Eczema, Pruritus, Rash
Clinical narrative: Rash diagnosed as eczema by dermatologist; itching terrible; Rash on the chest/rash getting worse and spread to both upper arms; This spontaneous case was reported by a consumer and describes the occurrence of ECZEMA (Rash diagnosed as eczema by dermatologist), PRURITUS (itching terrible) and RASH (Rash on the chest/rash getting worse and spread to both upper arms) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011A21A and 041L20A) for COVID-19 vaccination.     Concurrent medical conditions included Arthritis. Concomitant products included IBUPROFEN (ADVIL [IBUPROFEN]) for Arthritis, RALOXIFENE HYDROCHLORIDE (EVISTA), HYDRALAZINE HYDROCHLORIDE (DIAZIDE [HYDRALAZINE HYDROCHLORIDE]), COLECALCIFEROL (VITAMIN D3) and CITRA CALCEMIN for an unknown indication.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Mar-2021, the patient experienced RASH (Rash on the chest/rash getting worse and spread to both upper arms). On 04-Mar-2021, the patient experienced PRURITUS (itching terrible). On an unknown date, the patient experienced ECZEMA (Rash diagnosed as eczema by dermatologist). The patient was treated with PREDNISONE for Eczema, at an unspecified dose and frequency and TRIAMCINOLONE ACETONIDE (KENALOG [TRIAMCINOLONE ACETONIDE]) for Eczema, at a dose of twice a day. On 07-Mar-2021, PRURITUS (itching terrible) had resolved. On 09-Mar-2021, RASH (Rash on the chest/rash getting worse and spread to both upper arms) had resolved. At the time of the report, ECZEMA (Rash diagnosed as eczema by dermatologist) had resolved.            This case was linked to MOD-2021-017199 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 01-Jul-2021: Reporter address updated. On 03-Aug-2021: Follow-up contains events and the details were updated.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy, Tenderness, Vaccination site pruritus, Vaccination site warmth
Clinical narrative: Hotness at injection site; Tenderness at injection site; Itchiness at injection site; Pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant), VACCINATION SITE WARMTH (Hotness at injection site), TENDERNESS (Tenderness at injection site) and VACCINATION SITE PRURITUS (Itchiness at injection site) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 18-Dec-2021. On 14-Apr-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant). On 15-Apr-2021, the patient experienced VACCINATION SITE WARMTH (Hotness at injection site), TENDERNESS (Tenderness at injection site) and VACCINATION SITE PRURITUS (Itchiness at injection site). The patient was treated with PARACETAMOL (TYLENOL) (oral) for Adverse event, at a dose of UNK (4 times every 6 hrs). On 14-Apr-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) had resolved. On 20-Apr-2021, VACCINATION SITE WARMTH (Hotness at injection site), TENDERNESS (Tenderness at injection site) and VACCINATION SITE PRURITUS (Itchiness at injection site) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Patient was six weeks pregnant at the time of vaccination.
Sex: U
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (rash). At the time of the report, RASH (rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 95.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: 1st dose over 42 days ago; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (1st dose over 42 days ago) in a 95-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 01321A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure abnormal, Gout, Pain, Nausea and Gastrointestinal disorder NOS. Concomitant products included AMLODIPINE for Blood pressure abnormal, PANTOPRAZOLE for Gastrointestinal disorder NOS, ALLOPURINOL for Gout, MEGESTROL for Hormone therapy, MECLIZINE [MECLOZINE] and CYPROHEPTADINE for Nausea, TRAMADOL for Pain, VITAMINS NOS for Vitamin supplementation, HYDROXYCHLOROQUINE for an unknown indication.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (1st dose over 42 days ago). On 04-Mar-2021, PRODUCT DOSE OMISSION ISSUE (1st dose over 42 days ago) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reportedly, the patient got first dose of vaccine on 04-Mar-2021 however did not receive her second dose as on day of reporting. No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: Dental paraesthesia, Dysgeusia, Gingival pain, Myalgia, Pain in jaw
Clinical narrative: teeth sensitive to the cold / front teeth felt like she was eating ice cream; teeth felt like they were tingling; middle, upper, and lower areas of her jaw ache; food tastes bitter; upper right side ached / ached / ache slowly became more pronounced / strong ache; This spontaneous case was reported by a consumer and describes the occurrence of GINGIVAL PAIN (teeth sensitive to the cold / front teeth felt like she was eating ice cream), MYALGIA (upper right side ached / ached / ache slowly became more pronounced / strong ache), DENTAL PARAESTHESIA (teeth felt like they were tingling), PAIN IN JAW (middle, upper, and lower areas of her jaw ache) and DYSGEUSIA (food tastes bitter) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced GINGIVAL PAIN (teeth sensitive to the cold / front teeth felt like she was eating ice cream), MYALGIA (upper right side ached / ached / ache slowly became more pronounced / strong ache), DENTAL PARAESTHESIA (teeth felt like they were tingling), PAIN IN JAW (middle, upper, and lower areas of her jaw ache) and DYSGEUSIA (food tastes bitter). At the time of the report, DENTAL PARAESTHESIA (teeth felt like they were tingling), PAIN IN JAW (middle, upper, and lower areas of her jaw ache) and DYSGEUSIA (food tastes bitter) outcome was unknown.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: Reporting you my side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Reporting you my side effects.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Reporting you my side effects.). At the time of the report, VACCINATION COMPLICATION (Reporting you my side effects.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.        no concomitant medications and treatment medications was provided.